The professional's guide to product selection
For the prophylaxis of asthma.
• Over 12 years: 160 micrograms once daily; reduced to 80 micrograms once daily, if control maintained; increased if necessary up to 320 micrograms twice daily, in severe asthma.
For the prophylaxis of asthma by inhalation of powder
Child 5-11 years: 100–200 micrograms twice daily, dose to be adjusted as necessary.
Over 12 years: 200–400 micrograms twice daily; increased if necessary up to 800 micrograms twice daily, dose to be adjusted as necessary.
For the prophylaxis and treatment of allergic and vasomotor rhinitis by intranasal administration
• Over 6 years: 100 mcg twice daily, dose to be administered into each nostril. Maximum of 400 mcg per day. Reduce to 50 mcg twice daily if symptoms are controlled.
For the prophylaxis of asthma by inhalation of powder
Child 5-11 years: 100–200 micrograms twice daily, dose to be adjusted as necessary.
Over 12 years: 200–400 micrograms twice daily; increased if necessary up to 800 micrograms twice daily, dose to be adjusted as necessary.
For the prophylaxis and treatment of allergic and vasomotor rhinitis by intranasal administration
• Over 6 years: 100 mcg twice daily, dose to be administered into each nostril. Maximum of 400 mcg per day. Reduce to 50 mcg twice daily if symptoms are controlled.
For the prophylaxis of asthma with Qvar® preparations by inhalation of aerosol
Child 5–11 years: 50–100 mcg twice daily, using Autohaler or MDI device.
Child 12–17 years: 50–200 mcg twice daily; increased if necessary up to 400 mcg twice daily, using Autohaler, MDI, or Easi-Breathe device.
Adult: 50–200 mcg twice daily; increased if necessary up to 400 mcg twice daily, using Autohaler, MDI, or Easi-Breathe device.
For the prophylaxis and treatment of allergic and vasomotor rhinitis by intranasal administration
• Over 6 years: 100 mcg twice daily, dose to be administered into each nostril. Maximum of 400 mcg per day. Reduce to 50 mcg twice daily if symptoms are controlled.
For the prophylaxis and treatment of allergic and vasomotor rhinitis by intranasal administration
• Over 6 years: 100 mcg twice daily, dose to be administered into each nostril. Maximum of 400 mcg per day. Reduce if symptoms are controlled.
For the prophylaxis and treatment of asthma by inhalation of powder
• Child 5-11 years: 100–200 mcg twice daily, dose to be adjusted as necessary.
• Child 12–17 years: 200–400 mcg twice daily; increased if necessary up to 800 mcg twice daily, dose to be adjusted as necessary.
• Adult: 200–400 mcg twice daily; increased if necessary up to 800 mcg twice daily, dose to be adjusted as necessary.
For the prophylaxis and treatment of allergic and vasomotor rhinitis
• Over 6 years: 100 mcg twice daily, dose to be administered into each nostril. Maximum of 400 mcg per day. Reduce to 50 mcg twice daily if symptoms are controlled.
For the prophylaxis and treatment of asthma by inhalation of powder
• Child 5-11 years: 100–200 mcg twice daily, dose to be adjusted as necessary.
• Child 12–17 years: 200–400 mcg twice daily; increased if necessary up to 800 mcg twice daily, dose to be adjusted as necessary.
• Adult: 200–400 mcg twice daily; increased if necessary up to 800 mcg twice daily, dose to be adjusted as necessary.
For the prophylaxis and treatment of allergic and vasomotor rhinitis
• Over 6 years: 100 mcg twice daily, dose to be administered into each nostril. Maximum of 400 mcg per day. Reduce to 50 mcg twice daily if symptoms are controlled.
By mouth
• Adult: usual range 0.5–5 mg daily.
By intramuscular injection or by slow intravenous injection or infusion
• Adult: 4–20 mg, repeated up to 4 times in 24 hours.
By mouth
• Adult: usual range 0.5–5 mg daily.
By intramuscular injection or by slow intravenous injection or infusion
• Adult: 4–20 mg, repeated up to 4 times in 24 hours.
By mouth
• Adult: usual range 0.5–5 mg daily.
By intramuscular injection or by slow intravenous injection or infusion
• Adult: 4–20 mg, repeated up to 4 times in 24 hours.
By mouth
• Adult: usual range 0.5–5 mg daily.
By intramuscular injection or by slow intravenous injection or infusion
• Adult: 4–20 mg, repeated up to 4 times in 24 hours.
By mouth
• Adult: usual range 0.5–5 mg daily.
By intramuscular injection or by slow intravenous injection or infusion
• Adult: 4–20 mg, repeated up to 4 times in 24 hours.
By mouth
• Adult: usual range 0.5–5 mg daily.
By intramuscular injection or by slow intravenous injection or infusion
• Adult: 4–20 mg, repeated up to 4 times in 24 hours.
By mouth
• Adult: usual range 0.5–5 mg daily.
By intramuscular injection or by slow intravenous injection or infusion
• Adult: 4–20 mg, repeated up to 4 times in 24 hours.
By mouth
• Adult: usual range 0.5–5 mg daily.
By intramuscular injection or by slow intravenous injection or infusion
• Adult: 4–20 mg, repeated up to 4 times in 24 hours.
Budelin Novoliser for prophylaxis of asthma by inhalation of powder
• Adult: 200–800 mcg twice daily
Budelin Novoliser as an alternative in mild to moderate asthma by inhalation of powder, for patients previously stabilised on a twice-daily dose
• Adult: 200–400 mcg once daily to be taken in the evening. Maximum per dose 800 mcg.
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis of mild to moderate asthma by inhalation of powder
• Child 6 months–11 years: 200–400 micrograms once daily, dose to be given in the evening.
• Over 12 years: 200–400 micrograms once daily (max. per dose 800 micrograms), dose to be given in the evening.
Prophylaxis of asthma by inhalation of powder
• Child 6 months–11 years: 100–400 micrograms twice daily, dose to be adjusted as necessary.
• Over 12 years: 100–800 micrograms twice daily, dose to be adjusted as necessary.
Prophylaxis as treatment of allergic and vasomotor rhinitis by intranasal administration
• Child 6-17 years: 256 micrograms once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved, alternatively 128 micrograms twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
• Adult: 256 micrograms once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved, alternatively 128 micrograms twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis of mild to moderate asthma by inhalation of powder
• Child 6 months–11 years: 200–400 micrograms once daily, dose to be given in the evening.
• Over 12 years: 200–400 micrograms once daily (max. per dose 800 micrograms), dose to be given in the evening.
Prophylaxis of asthma by inhalation of powder
• Child 6 months–11 years: 100–400 micrograms twice daily, dose to be adjusted as necessary.
• Over 12 years: 100–800 micrograms twice daily, dose to be adjusted as necessary.
Prophylaxis as treatment of allergic and vasomotor rhinitis by intranasal administration
• Child 6-17 years: 256 micrograms once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved, alternatively 128 micrograms twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
• Adult: 256 micrograms once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved, alternatively 128 micrograms twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
Prophylaxis of mild to moderate asthma by inhalation of powder
• Child 6 months–11 years: 200–400 micrograms once daily, dose to be given in the evening.
• Over 12 years: 200–400 micrograms once daily (max. per dose 800 micrograms), dose to be given in the evening.
Prophylaxis of asthma by inhalation of powder
• Child 6 months–11 years: 100–400 micrograms twice daily, dose to be adjusted as necessary.
• Over 12 years: 100–800 micrograms twice daily, dose to be adjusted as necessary.
Prophylaxis as treatment of allergic and vasomotor rhinitis by intranasal administration
• Child 6-17 years: 256 micrograms once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved, alternatively 128 micrograms twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
• Adult: 256 micrograms once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved, alternatively 128 micrograms twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
For prophylaxis of asthma by inhalation of aerosol
• Child 2–11 years: 100–200 mcg twice daily.
• Over 12 years: 200–400 mcg twice daily, increased if necessary up to 1 mg twice daily. Adjust according to response.
• Child 1 month–11 years: 0.25–1.5 mg/kg daily (or on alternate days), increased if necessary up to 2.4 mg/kg daily (maximum 120 mg).
• Child 12–17 years: 3–18 mg once daily or on alternate days), increased if necessary up to 2.4 mg/kg daily (maximum 120 mg).
• Adult: 3–18 mg daily for maintenance. Acute disorders, initially up to 120 mg daily.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1–2 divided doses.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
Child: 150 mcg/kg for 1 dose
Severe croup by mouth
Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
Adult: 4–8 mg daily.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1 or 2 divided doses. Up to 300 mcg/kg can be given in emergency situations.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
• Child: 150 mcg/kg for 1 dose.
Severe croup by mouth
• Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
• Adult: 4–8 mg daily.
Covid-19 requiring supplemental oxygen
• Child: 150 mcg/kg once daily (max. per dose 6 mg) for 10 days, or until the day of discharge if this is sooner.
• Adult: 6 mg once daily for 10 days, or until the day of discharge if this is sooner.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1–2 divided doses.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
Child: 150 mcg/kg for 1 dose
Severe croup by mouth
Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
Adult: 4–8 mg daily.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1–2 divided doses.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
Child: 150 mcg/kg for 1 dose
Severe croup by mouth
Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
Adult: 4–8 mg daily.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1–2 divided doses.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
Child: 150 mcg/kg for 1 dose
Severe croup by mouth
Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
Adult: 4–8 mg daily.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1–2 divided doses.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
Child: 150 mcg/kg for 1 dose
Severe croup by mouth
Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
Adult: 4–8 mg daily.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1–2 divided doses.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
Child: 150 mcg/kg for 1 dose
Severe croup by mouth
Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
Adult: 4–8 mg daily.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1–2 divided doses.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
Child: 150 mcg/kg for 1 dose
Severe croup by mouth
Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
Adult: 4–8 mg daily.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1–2 divided doses.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
Child: 150 mcg/kg for 1 dose
Severe croup by mouth
Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
Adult: 4–8 mg daily.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1–2 divided doses.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
Child: 150 mcg/kg for 1 dose
Severe croup by mouth
Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
Adult: 4–8 mg daily.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1–2 divided doses.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
Child: 150 mcg/kg for 1 dose
Severe croup by mouth
Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
Adult: 4–8 mg daily.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1–2 divided doses.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
Child: 150 mcg/kg for 1 dose
Severe croup by mouth
Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
Adult: 4–8 mg daily.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1–2 divided doses.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
Child: 150 mcg/kg for 1 dose
Severe croup by mouth
Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
Adult: 4–8 mg daily.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1–2 divided doses.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
Child: 150 mcg/kg for 1 dose
Severe croup by mouth
Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
Adult: 4–8 mg daily.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1–2 divided doses.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
Child: 150 mcg/kg for 1 dose
Severe croup by mouth
Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
Adult: 4–8 mg daily.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
• Child: 150 mcg/kg for 1 dose
Severe croup by mouth
• Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
• Adult: 4–8 mg daily.
Covid-19 requiring supplemental oxygen, by mouth, or by intravenous injection
• Adult: 6 mg once daily for 10 days, or until the day of discharge if this is sooner.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1–2 divided doses.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
Child: 150 mcg/kg for 1 dose
Severe croup by mouth
Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
Adult: 4–8 mg daily.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1–2 divided doses.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
Child: 150 mcg/kg for 1 dose
Severe croup by mouth
Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
Adult: 4–8 mg daily.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1 or 2 divided doses. Up to 300 mcg/kg can be given in emergency situations.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
• Child: 150 mcg/kg for 1 dose.
Severe croup by mouth
• Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
• Adult: 4–8 mg daily.
Covid-19 requiring supplemental oxygen
• Child: 150 mcg/kg once daily (max. per dose 6 mg) for 10 days, or until the day of discharge if this is sooner.
• Adult: 6 mg once daily for 10 days, or until the day of discharge if this is sooner.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1 or 2 divided doses. Up to 300 mcg/kg can be given in emergency situations.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
• Child: 150 mcg/kg for 1 dose.
Severe croup by mouth
• Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
• Adult: 4–8 mg daily.
Covid-19 requiring supplemental oxygen
• Child: 150 mcg/kg once daily (max. per dose 6 mg) for 10 days, or until the day of discharge if this is sooner.
• Adult: 6 mg once daily for 10 days, or until the day of discharge if this is sooner.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
• Child: 150 mcg/kg for 1 dose
Severe croup by mouth
• Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
• Adult: 4–8 mg daily.
Covid-19 requiring supplemental oxygen, by mouth, or by intravenous injection
• Adult: 6 mg once daily for 10 days, or until the day of discharge if this is sooner.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1 or 2 divided doses. Up to 300 mcg/kg can be given in emergency situations.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
• Child: 150 mcg/kg for 1 dose.
Severe croup by mouth
• Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
• Adult: 4–8 mg daily.
Covid-19 requiring supplemental oxygen
• Child: 150 mcg/kg once daily (max. per dose 6 mg) for 10 days, or until the day of discharge if this is sooner.
• Adult: 6 mg once daily for 10 days, or until the day of discharge if this is sooner.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1 or 2 divided doses. Up to 300 mcg/kg can be given in emergency situations.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
• Child: 150 mcg/kg for 1 dose.
Severe croup by mouth
• Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
• Adult: 4–8 mg daily.
Covid-19 requiring supplemental oxygen
• Child: 150 mcg/kg once daily (max. per dose 6 mg) for 10 days, or until the day of discharge if this is sooner.
• Adult: 6 mg once daily for 10 days, or until the day of discharge if this is sooner.
Suppression of inflammatory and allergic disorders by mouth
• Child: 10–100 mcg/kg daily in 1 or 2 divided doses. Up to 300 mcg/kg can be given in emergency situations.
• Adult: 0.5–10 mg daily.
Mild croup by mouth
• Child: 150 mcg/kg for 1 dose.
Severe croup by mouth
• Child: initially 150 mcg/kg before transfer to hospital, then an additional dose, then another after 12 hours if required.
Dyspnoea due to bronchospasm or partial obstruction in palliative care
• Adult: 4–8 mg daily.
Covid-19 requiring supplemental oxygen
• Child: 150 mcg/kg once daily (max. per dose 6 mg) for 10 days, or until the day of discharge if this is sooner.
• Adult: 6 mg once daily for 10 days, or until the day of discharge if this is sooner.
For allergic rhinitis
• Over 12 years: one spray twice daily, dose to be administered into each nostril.
Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
For the prophylaxis of asthma by inhalation of powder
• Child 5–15 years: initially 50–100 mcg twice daily (maximum per dose 200 mcg twice daily), dose to be adjusted as required.
• Over 16 years: initially 100–500 mcg twice daily (maximum per dose 1 mg twice daily). Dose may be increased according to severity of asthma. Doses above 500 mcg twice daily initiated by a specialist.
For the prophylaxis of asthma by inhalation of aerosol
• Child 4–15 years: initially 50–100 mcg twice daily (maximum per dose 200 mcg twice daily), dose to be adjusted as required.
• Over 16 years: initially 100–500 mcg twice daily (maximum per dose 1 mg twice daily). Dose may be increased according to severity of asthma. Doses above 500 mcg twice daily initiated by a specialist.
For the prophylaxis of asthma by inhalation of nebulised suspension
• Child 4–15 years: 1 mg twice daily.
• Over 16 years: 0.5–2 mg twice daily.
Prophylaxis treatment of allergic and perennial rhinitis by nasal spray
• Child 4–11 years: 50 mcg once daily to be administered to each nostril preferably in the morning. Increase if necessary to 50 mcg twice daily.
• Over 12 years: 100 mcg once daily to be administered to each nostril preferably in the morning. Increase if necessary to 100 mcg twice daily. Reduce to 50 mcg once daily when controlled.
Prophylaxis treatment of nasal polyps by nasal spray
• Over 16 years: 200 mcg one to two times per
day administered into each nostril. If no improvement in four to six weeks, consider alternative treatment.
For nasal polyps using nasal drops
Over 16 years: 200 mcg 1–2 times a day, to be administered into each nostril, alternative treatment should be considered if no improvement after 4–6 weeks, (200 mcg is equivalent to approximately 6 drops).
Long-acting selective beta2 agonist with corticosteroid.
Seretide 100 Accuhaler
• 4 years and over for asthma prophylaxis: one inhalation twice daily, reduce to one inhalation daily if controlled.
Seretide 250 Accuhaler
• 12 years and over for asthma prophylaxis: one inhalation twice daily.
Seretide 500 Accuhaler
• 12 years and over for asthma prophylaxis: one inhalation twice daily.
• Adult for COPD with FEV1 in one second <60% of predicted: one inhalation twice daily.
Seretide 50 Evohaler
• 4 years and over for asthma prophylaxis: two puffs twice daily, reduce to two puffs once daily if controlled.
Seretide 125 Evohaler
• 12 years and over for asthma prophylaxis: two puffs twice daily.
Seretide 250 Evohaler
• 12 years and over for asthma prophylaxis: two puffs twice daily.
Long-acting selective beta2 agonist with corticosteroid.
Combisal 25/125
• Over 12 years for prophylaxis of asthma: two inhalations twice daily.
Combisal 25/50
• Over 4 years for prophylaxis of asthma: two inhalations twice daily, but can be reduced to two inhalations once daily.
Combisal 25/250
• Over 12 years for prophylaxis of asthma: two inhalations twice daily.
Long-acting selective beta2 agonist with corticosteroid.
Sereflo Ciphaler 50/250 for prophylaxis of asthma
• Over 12 years: 1 inhalation twice daily, reduced to 1 inhalation once daily, use reduced dose only if control maintained.
Sereflo 125 for moderate to serve asthma
• Adult: 2 inhalations twice daily.
Sereflo 250 for moderate to severe asthma
• Adult: 2 inhalations twice daily.
Long-acting selective beta2 agonist with corticosteroid.
Stalpex 500/50 mcg
• For symptomatic treatment of COPD with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
• Adult: one inhalation twice daily.
Stalpex is indicated for use in patients with severe asthma 12 years of age and older only, where patients not adequately controlled on a lower strength corticosteroid combination product; or patients already adequately controlled on an inhaled corticosteroid in a high strength and a long-acting beta2 agonist.
• Adults and adolescents 12 years and older: One inhalation, twice daily
Long-acting selective beta2 agonist with corticosteroid.
Fusacomb 50/250 Easyhaler
• 12 years and over for prophylaxis of asthma: one inhalation twice daily and can be reduced to once daily.
Fusacomb 50/500 Easyhaler
• 12 years and over for prophylaxis of asthma: one inhalation twice daily.
• Adult for COPD: one inhalation twice daily.
Long-acting selective beta2 agonist with corticosteroid.
AirFluSal 125
• Adult for prophylaxis of moderate to severe asthma: two inhalations twice daily.
AirFluSal 250
• Over 18 years for prophylaxis of moderate to severe asthma: two inhalations twice daily.
AirFluSal Forspiro
• Adult for severe asthma and COPD: one inhalation twice a day.
Long-acting selective beta2 agonist with corticosteroid.
Fixkoh Airmaster 50/250
• 12 years and over for prophylaxis of asthma: one inhalation twice daily.
Fixkoh Airmaster 50/100
• 12 years and over for prophylaxis of asthma: one inhalation twice daily but can be reduced to once daily.
Fixkoh Airmaster 50/500
• 12 years and over for prophylaxis of asthma: one inhalation twice daily.
• Adult for COPD: 1 inhalation twice daily.
Long-acting selective beta2 agonist with corticosteroid.
Relvar Ellipta 92 mcg/22 mcg
• Over 12 years for prophylaxis of asthma: one inhalation once daily.
• Adult for COPD: one inhalation once daily.
Relvar Ellipta 184 mcg/22 mcg
• Over 12 years for prophylaxis of asthma: one inhalation once daily.
Long acting muscarinic antagonist, long-acting beta 2 agonist and inhaled corticosteroid. Two inhalations twice daily
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
Long-acting selective beta2 agonist with corticosteroid.
For prophylaxis of asthma
Atectura Breezhaler 125/62.5
Atectura Breezhaler 125/260
Atectura Breezhaler 125/127.5
Adult: one inhalation once daily.
For prophylaxis of asthma by inhalation of aerosol. Kelhale has extra-fine particles and is more potent than traditional beclomethasone diproprionate inhalers.
• Adult: 50–200 mcg twice daily, increased if necessary to 400 mcg twice daily
Long-acting selective beta2 agonist with corticosteroid.
Asthma maintenance therapy for Luforbec® 100/6 by inhalation of aerosol
Adult: 1–2 inhalations twice daily; maximum 4 inhalations per day.
Asthma, maintenance and reliever therapy for Luforbec® 100/6 by inhalation of aerosol
Adult: 1 inhalation twice daily; 1 inhalation as required, for relief of symptoms; maximum 8 inhalations per day.
Chronic obstructive pulmonary disease with forced expiratory volume in 1 second < 50% of predicted for Luforbec® 100/6 by inhalation of aerosol
Adult: 2 inhalations twice daily.
Asthma maintenance therapy for Luforbec® 200/6 by inhalation of aerosol
Adult: 2 inhalations twice daily, maximum 4 inhalations per day.
Children and adolescents aged less than 18 years must not take this medicine
By mouth for the suppression of inflammatory and allergic disorders
• Adult: 2–40 mg daily.
By intramuscular injection or slow intravenous injection or infusion for the suppression of inflammatory and allergic disorders
• Adult: initially 10–500 mg.
By mouth for the suppression of inflammatory and allergic disorders
• Adult: 2–40 mg daily.
By intramuscular injection or slow intravenous injection or infusion for the suppression of inflammatory and allergic disorders
• Adult: initially 10–500 mg.
Depo-Medrone by deep intramuscular injection into gluteal muscle for the suppression of inflammatory and allergic disorders
• Adult: 40–120 mg, a second injection may be given after 2–3 weeks if required.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
For prophylaxis of asthma by inhalation of powder
• Child 12–17 years: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained.
• Adult: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained.
For prophylaxis of severe asthma by inhalation of powder
• Child 12–17 years: Increased if necessary up to 400 micrograms twice daily.
• Adult: Increased if necessary up to 400 micrograms twice daily.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
For prophylaxis of asthma by inhalation of powder
• Child 12–17 years: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained.
• Adult: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained.
For prophylaxis of severe asthma by inhalation of powder
• Child 12–17 years: Increased if necessary up to 400 micrograms twice daily.
• Adult: Increased if necessary up to 400 micrograms twice daily.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.
Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.
Long-acting selective beta2 agonist, long-acting muscarinic antagonist with corticosteroid.
Adult: one inhalation once daily.
By intranasal administration for prophylaxis and treatment of allergic rhinitis
• Child 6–11 years: 55 mcg once daily, dose into each nostril, increased if necessary to 110 mcg daily. Reduce dose when controlled. Maximum duration 3 months.
• Over 12 years: 110 mcg once daily, dose into each nostril. Reduce to 55 mcg once daily when controlled.
For the prophylaxis and treatment of allergic and vasomotor rhinitis by intranasal administration
• Over 6 years: 100 mcg twice daily, dose to be administered into each nostril. Maximum of 400 mcg per day. Reduce to 50 mcg twice daily if symptoms are controlled.
Prophylaxis treatment of allergic and perennial rhinitis by nasal spray
• Child 4–11 years: 50 mcg once daily to be administered to each nostril preferably in the morning. Increase if necessary to 50 mcg twice daily.
• Over 12 years: 100 mcg once daily to be administered to each nostril preferably in the morning. Increase if necessary to 100 mcg twice daily. Reduce to 50 mcg once daily when controlled.
Prophylaxis treatment of nasal polyps by nasal spray
• Over 16 years: 200 mcg one to two times per
day administered into each nostril. If no improvement in four to six weeks, consider alternative treatment.
For the treatment of anaphylaxis and asthma.
By intravenous injection for acute hypersensitivity reactions
• Adult: 100–300 mg, to be administered as sodium succinate.
By intramuscular injection, or by intravenous injection for acute hypersensitivity reactions
• Child 1–5 months: initially 25 mg three times a day, adjust according to response.
• Child 6 months–5 years: initially 50 mg three times a day, adjust according to response.
• Child 6–11 years: initially 100 mg three times a day, adjust according to response.
• Child 12–17 years: initially 200 mg three times a day, adjust according to response.
By intravenous injection for severe acute asthma
• Child 1 month–1 year: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 25 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 2–4 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 50 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 5–11 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Child 12–17 years: 4 mg/kg every six hours. Maximum per dose 100 mg. Alternatively 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
• Adult: 100 mg every six hours until conversion to oral prednisolone. Preferably administer as sodium succinate.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
By mouth for acute exacerbation of chronic obstructive pulmonary disease
• Adult: 30 mg daily for 7–14 days.
By mouth for severe croup or mild croup that might cause complications (before transfer to hospital)
• Child: 1–2 mg/kg.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma when oral corticosteroids have been taken for a few days
• Child 1 month–11 years: 2 mg/kg once daily (maximum dose 60 mg) for up to three days, longer if necessary.
By mouth for mild to moderate acute asthma or severe or life-threatening asthma
• Child 1 month–11 years: 1–2 mg/kg once daily (maximum dose 40 mg) for up to three days, longer if necessary.
• Over 12 years: 40–50 mg daily for at least five days.
By mouth for suppression of inflammatory and allergic disorders
• Adult: initially 10–20 mg daily, preferably taken in the morning after food. Can often be reduced after a few days but may need to be continued for a few weeks or months. Maintenance 2.5–15 mg daily. Cushingoid side-effects increase in likelihood with doses of over 7.5 mg daily.
By mouth for suppression of inflammatory and allergic disorders (initial dose in severe disease)
• Adult: initially up to 60 mg daily, dose preferably taken in the morning after food. Can often be reduced within a few days but may need to be continued for a few weeks or months.
By mouth for Covid-19 requiring supplementary oxygen
• Adult: 40 mg daily, for 10 days or until the day of discharge, whichever is sooner.
Corticosteroid.
Pulmicort Respules for prophylaxis of asthma by inhalation of nebulised suspension
• Child 3 months–11 years: initially 0.5–1 mg twice daily then reduce to 250–500 mcg twice daily.
• Over 12 years: initially 1–2 mg twice daily then reduce to 0.5–1 mg twice daily.
Corticosteroid.
Pulmicort Turbohaler for prophylaxis of asthma by inhalation of powder.
• Adult: 100–800 mcg twice daily
Pulmicort Turbohaler as an alternative in mild to moderate asthma by inhalation of powder, for patients previously stabilised on a twice daily dose.
• Adult: 200–400 mcg once daily to be taken in the evening.
Qvar for prophylaxis of asthma by inhalation of aerosol. Qvar has extra-fine particles and is more potent than traditional beclomethasone diproprionate inhalers.
• Child 5–11 years: 50–100 mcg twice daily using Autohaler or MDI device.
• Over 12 years: 50–200 mcg twice daily, can be increased if necessary to 400 mcg twice daily using Autohaler, MDI or Easi-Breathe device.
Soprobec is indicated for the maintenance treatment of asthma, when the use of pressurised metered dose inhaler is appropriate.
Long-acting selective beta2 agonist with corticosteroid.
Symbicort 100/3 pressurised inhaler
Asthma, maintenance therapy
• Child 12–17 years: Initially 2–4 inhalations twice daily; reduced to 1 inhalation daily, dose reduced only if control is maintained.
• Adult: Initially 2–4 inhalations twice daily, increased if necessary up to 8 inhalations twice daily; reduced to 1 inhalation daily, dose reduced only if control is maintained.
Asthma, maintenance and reliever therapy
• Over 12 years: Maintenance 4 inhalations daily in 1–2 divided doses, increased if necessary up to 4 inhalations twice daily; 2 inhalations as required for relief of symptoms, increased if necessary up to 12 inhalations as required, usual max. 16 inhalations per day; up to 24 inhalations daily can be used for a limited time under medical supervision.
Symbicort 200/6 Pressurised inhaler
COPD
• Adult: 2 inhalations twice daily.
Long-acting selective beta2 agonist with corticosteroid.
Symbicort 100/6 Turbohaler
• 6–17 years for asthma maintenance: 1-2 inhalations twice daily, reduced to 1 inhalation daily if controlled.
• Adults for asthma maintenance: 1-2 inhalations daily, increased to up to 4 inhalations daily if needed, or reduced to 1 daily if controlled.
• Over 12 years for asthma maintenance and reliever therapy: 2 inhalations daily across one or two doses; 1 inhalation for relief of symptoms and increase to 6 if required. A maximum of 8 inhalations per day, but 12 can be given under medical supervision.
Symbicort 200/6 Turbohaler
• 12–17 years for asthma maintenance: 1-2 inhalations twice daily, reduced to 1 inhalation daily if controlled.
• Adults for asthma maintenance: 1-2 inhalations daily, increased to up to 4 inhalations daily if needed, or reduced to one daily if controlled.
• Over 12 years for asthma maintenance and reliever therapy: 2 inhalations daily across one or two doses but can be increased to 2 inhalations twice daily if needed; 1 inhalation for relief of symptoms and increase to 6 inhalations if required. A maximum of 8 inhalations per day, but 12 can be given for a limited time under medical supervision.
• Adult for COPD: 1 inhalation twice daily.
Symbicort 400/12 Turbohaler
• 12–17 years for asthma maintenance: 1 inhalation twice daily, but can be reduced to 1 inhalation daily.
• Adult for asthma maintenance: 1 inhalation twice daily, increased to 2 inhalations twice daily if required and decreased to 1 inhalation daily if controlled.
• Adult for COPD: 1 inhalation twice daily.
Long-acting muscarinic antagonist, Long-acting selective beta2 agonist with corticosteroid.
Adult for moderate COPD: one inhalation once daily – to be taken at the same time each day.
By deep intramuscular injection into the gluteal for suppression of inflammatory and allergic disorders
• Adult: 40 mg (maximum dose of 100 mg), repeated if necessary.
For non-infected inflammatory conditions of nose using Vistamethasone® by intranasal administration
Adult: Apply 2–3 drops twice daily, dose to be applied into each nostril.